These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35094622)

  • 1. Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
    Yale JF; Osumili B; Mitchell BD; Hunt B; Sohi G; Jeddi M; Mojdami D; Valentine WJ
    J Med Econ; 2022; 25(1):238-248. PubMed ID: 35094622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
    Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
    J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model.
    Leinwand B; Johnsrud M; Nguyen A; Meyer J; Johnson K
    J Med Econ; 2020 Jul; 23(7):744-750. PubMed ID: 32162983
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
    Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
    J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
    [No Abstract]   [Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of hypoglycemia among insulin-treated patients with diabetes.
    Sussman M; Sierra JA; Garg S; Bode B; Friedman M; Gill M; Kaufman F; Vigersky R; Menzin J
    J Med Econ; 2016 Nov; 19(11):1099-1106. PubMed ID: 27292016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.
    Yale JF; Dulude H; Egeth M; Piché CA; Lafontaine M; Carballo D; Margolies R; Dissinger E; Shames AR; Kaplowitz N; Zhang MX; Zhang S; Guzman CB
    Diabetes Technol Ther; 2017 Jul; 19(7):423-432. PubMed ID: 28556672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan.
    Ikeda Y; Kubo T; Oda E; Abe M; Tokita S
    J Diabetes Investig; 2019 May; 10(3):857-865. PubMed ID: 30325576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.
    Thayer S; Wei W; Buysman E; Brekke L; Crown W; Grabner M; Raparla S; Quimbo R; Cziraky MJ; Hu W; Cuddihy R
    Adv Ther; 2013 Dec; 30(12):1128-40. PubMed ID: 24293131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
    La Sala L; Pontiroli AE
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
    Pollock RF; Norrbacka K; Cameron C; Mancillas-Adame L; Jeddi M
    J Comp Eff Res; 2019 Mar; 8(4):229-240. PubMed ID: 30644328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia.
    Pontiroli AE; Tagliabue E
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain.
    Osumili B; Artime E; Mitchell B; Rubio-de Santos M; Díaz-Cerezo S; Giménez M; Spaepen E; Sharland H; Valentine WJ
    Diabetes Ther; 2022 Apr; 13(4):775-794. PubMed ID: 35297026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
    Deeb LC; Dulude H; Guzman CB; Zhang S; Reiner BJ; Piché CA; Pradhan S; Zhang XM
    Pediatr Diabetes; 2018 Aug; 19(5):1007-1013. PubMed ID: 29512902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Health-Care Costs and Productivity Costs Associated With Hypoglycemia in Adults With Type 1 and Type 2 Diabetes Mellitus That Participated in the Canadian Hypoglycemia Assessment Tool Program.
    O'Reilly DJ; Burke N; Tarride JE; Hahn J; Nurkanovic L
    Can J Diabetes; 2018 Dec; 42(6):659-663. PubMed ID: 29885881
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.